Endo's Belbuca Is First Buccal Film In Extended-Release Opioid Class
This article was originally published in The Pink Sheet Daily
Executive Summary
While Belbuca represents a new formulation, it does not contain the abuse-deterrent properties that FDA has been encouraging.
You may also be interested in...
Collegium, BioDelivery To Combine Pain Portfolios In Proposed Merger
Collegium has offered a 54% share premium to acquire competitor BioDelivery, in an offer approved by both firm’s boards. The $604m price tag would double the size of Collegium’s product portfolio.
Opioid Post-marketing Studies: Can Sponsors Work Well Together Again?
FDA wants to get a handle on how long-term use of long-acting pain killers relates to abuse and misuse; the agency also is requiring labeling changes that remove “moderate” pain from the products’ indication.
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.